Diagnosis

Systemic lupus erythematosus

A chronic autoimmune disorder characterized by multisystem autoantibody response to nuclear and cytoplasmic antigens.

Etiology

Cause [sgp]

Pathophysiology [e9b][sgp]

  1. Genetically susceptible individuals + environmental trigger --> autoimmunity

  2. Infection or environmental factor --> cell damage

  3. Defect in apoptosis --> cell-surface display of cytoplasmic and nuclear antigens --> immune system exposed to self-antigens

  4. Dysregulated (intolerant) T and B lymphocytes targets normally protected intracellular antigens --> chronic self-aimed immune response:

    • Cytokine release

    • Complement activation

    • Autoantibody production

    • Organ damage

  5. Clinical presentation:

    • General: Fatigue, fever, arthralgia, myalgia, lymphadenopathy, splenomegaly

    • Dermatologic: Lupus-specific lesions

      • Acute cutaneous lupus: localized, malar/butterfly, and generalized rash

      • Subacute cutaneous lupus: annular and papulosquamous rash

      • Chronic cutaneous lupus: discoid lupus, hypertrophic/verrucous, lupus panniculitis/profundus, lupus tumidus, chilblains lupus, mucosal discoid lupus, and lichenoid discoid lupus

    • Mucosa: Oral and nasal ulcers, Sjogren syndrome, keratoconjunctivitis sicca

    • Renal failure: Lupus nephritis

    • Psychiatric: depression, anxiety, psychosis

    • CNS: headache, stroke, seizure, aseptic meningitis, demyelinating syndrome (optic neuritis, myelitis), chorea, cognitive dysfunction, neuropathy, mononeuritis multiplex, autonomic neuropathy, Guillain-Barré syndrome, Myasthenia gravis

    • Pulmonary: Pneumonitis, pleuritis, pleural effusion, pulmonary hypertension, pulmonary embolism

    • Gastrointestinal: Nausea, dyspepsia, abdominal pain, esophageal dysmotility, mesenteric vasculitis, lupus enteritis, peritonitis, ascites, protein-losing enteropathy, pancreatitis, lupoid hepatitis, Budd-Chiari syndrome, mesenteric vessel thrombosis

    • Cardiac: Pericarditis, myocarditis, Libman-Sacks endocarditis

    • Vasculitis

    • Thrombotic microangiopathy

    • Hematologic: Leukopenia, lymphopenia, anemia, thrombocytopenia

    • Obstetric: Risk of spontaneous abortions and fetal loss, pre-eclampsia, and maternal thrombosis

    • Ocular: retinal vasculitis, optic neuritis, uveitis, scleritis, peripheral ulcerative keratitis, episcleritis, glaucoma or cataract

    • Sudden sensorineural hearing loss

Complications [sgp]

Epidemiology

Incidence per 100.000 [htu][3nw][dk2][wnv][mwy][zvs][bs6][pao][q4p][ush]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Anasarca, Anorexia, Arrhythmia, Arthralgia, Arthritis, Cough, Delirium, Dyspepsia, Dyspnea, Edema, Fatigue, Fever, Hallucinations, Headache, Hematuria, Hemoptysis, Hypertension, Icterus, Lymphadenopathy, Malaise, Myalgia, Nausea, Paralysis, Paranoia, Paresis, Paresthesia, Photophobia, Psychosis, Seizure, Systolic murmur, Tachypnea, Weight gain, Weight loss

Clinical findings

ANA, Anemia, Anti-dsDNA antibody, Anti-phospholipid antibody, Anti-Smith antibody, Elevated Creatinine, Elevated CRP, Elevated Sedimentation Rate, Hypoxemia, Jaundice, Leukopenia, Lymphopenia, Myocarditis, Pericardial effusion, Pericarditis, Peritonitis, Pleural effusion, Pleuritis, Proteinuria, Pulmonary hypertension, Thrombocytopenia

Anamneses

None listed.

Localized findings

Pain
Radiates
ThoraxAbdomenRegio carpalis (Wrist)HandRegio genus
Onset
Gradual (days)
Pattern
ConstantIncreasing
Severity
Mild (1-3)Moderate (4-7)
Pain
Radiates
JointsMuscles
Onset
Gradual (days)
Pattern
Constant
Severity
Mild (1-3)Moderate (4-7)
Rash
Radiates
Regio nasalisRegio infraorbitalis
Distribution
LocalizedPhotodistributedSymmetric
Lesion type
ErythemaMacule
Lesion configuration
Confluent
Color
Red
Rash
Radiates
CaputCollumThoraxAbdomenGenitalArmBackLower body
Distribution
MultiplePhotodistributedSymmetric
Lesion type
AlopeciaBullaErosionErythemaPapulePlaquePurpuraScarTelangiectasiaUlcerUrticaria
Lesion configuration
Discoid/nummular
Lesion surface
Desquamation
Rash
Radiates
ArmLower body
Distribution
GeneralizedSymmetric
Lesion type
Mottling
Color
BlueRed
Palpation
Cold

Approach

SOAP BRAIN MD:

Rule out infections and drug reactions (procainamide, hydralazine, and isoniazid).

Treatment

Goal of treatment: induction of remission, consolidation of remission, and remission maintenance [yc9]

  1. Cutaneous/musculoskeletal/serositis SLE: milder disease [e9b][yc9]

    • NSAIDs

    • Hydroxychloroquine

    • Low-potency immunosuppressive medications

    • Short courses of corticosteroids

  2. Involvement of vital organs: [yc9][nhv]

    • Prednisone

    • Hydroxychloroquine

    • Azathioprine

    • Methotrexate

    • Mycophenolate Mofetil

    • Calcineurin inhibitors

    • Cyclophosphamide

    • Biologic: Rituximab, Belimumab, Anifrolumab

    • Other (plasmaferesis, intravenous immunologlobulins)

Differential diagnoses

Acute pancreatitis, Antiphospholipid syndrome, Behcet's disease, Cytomegalovirus, Drug side effects, Endocarditis, Erysipelas, Fibromyalgia, Guillain-Barre syndrome, Heart failure, HIV, Interstitial lung disease, Leukemia, Lyme disease, Lymphoma, Meningitis, Mixed connective tissue disease, Mononeuropathy, Mononucleosis, Myocarditis, Parvovirus B19, Pericarditis, Pneumonia, Polymyositis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Pulmonary embolism, Raynaud phenomenon, Renal failure, Rheumatoid arthritis, Rosacea, Sarcoidosis, Scleroderma, Seborrheic dermatitis, Sjogren syndrome, Still disease, Stroke, Thrombotic thrombocytopenic purpura, Ulcer disease, Viral hepatitis


References

[1] Justiz Vaillant AA, Goyal A, Varacallo MA. Systemic Lupus Erythematosus. [Updated 2023 Aug 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535405/

[2] http://emedicine.medscape.com/article/332244 (2014-01-27); [Medscape]

[3] Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. Arthritis Rheum. 2007 May 15;57(4):612-8.

[4] Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, Wing JJ, Dhar JP, Leisen J, Shaltis D, McCune WJ. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol. 2014 Feb;66(2):369-78.

[5] Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O. Incidence of systemic lupus erythematosus in Finland, 2000-2007, a nationwide study. Clin Exp Rheumatol. 2014 Nov-Dec;32(6):953-5. Epub 2014 Oct 20.

[6] Alexander T, Sewerin P, Strangfeld A, Schulte M, Borchert J, Garcia TB, Schrom E. Real-World Prevalence, Incidence and Management of Systemic Lupus Erythematosus in Germany: A Retrospective Claims Data Analysis. Rheumatol Ther. 2025 Apr;12(2):237-254.

[7] Li M, Li C, Cao M, Lu K, Wu C, Wang J, Wei C, Zhao J, Wang Q, Tian X, Tang X, Li M, Zeng X, Gao P. Incidence and prevalence of systemic lupus erythematosus in urban China, 2013-2017: A nationwide population-based study. Sci Bull (Beijing). 2024 Oct 15;69(19):3089-3097.

[8] Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. Lupus. 2020 Jan;29(1):15-26.

[9] Lerang K, Gilboe I, Garen T, Thelle DS, Gran JT. High incidence and prevalence of systemic lupus erythematosus in Norway. Lupus. 2012 Oct;21(12):1362-9.

[10] Haukeland H, Moe SR, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås HK, Bøe TB, Orre A, Garen T, Molberg Ø, Lerang K. Declining Incidence of Systemic Lupus Erythematosus in Norway 1999-2017: Data From a Population Cohort Identified by International Classification of Diseases, 10th Revision Code and Verified by Classification. Arthritis Rheumatol. 2024 May;76(5):715-725.

[11] Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, Askanase A, Bathon JM, Geraldino-Pardilla L, Ali Y, Ginzler EM, Putterman C, Gordon C, Helmick CG, Parton H. The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis Rheumatol. 2017 Oct;69(10):2006-2017.

[12] Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. Sci Rep. 2021 Mar 11;11(1):5631.

[13] Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatol Int. 2023 Aug;43(8):1395-1407.

[14] Tsioni V, Andreoli L, Meini A, Frassi M, Raffetti E, Airò P, Allegri F, Donato F, Tincani A. The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy. Clin Exp Rheumatol. 2015 Sep-Oct;33(5):681-7. Epub 2015 Jun 19.

Scroll to top